Obesity and kidney disease: hidden consequences of the epidemic

Abstract

Obesity has become a worldwide epidemic, and its prevalence has been projected to grow by 40% in the next decade. This increasing prevalence has implications for the risk of diabetes, cardiovascular disease and also for chronic kidney disease. A high body mass index is one of the strongest risk factors for new-onset chronic kidney disease. In individuals affected by obesity, a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased bodyweight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing chronic kidney disease in the long term. The incidence of obesity-related glomerulopathy has increased tenfold in recent years. Obesity has also been shown to be a risk factor for nephrolithiasis, and for a number of malignancies including kidney cancer. This year World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating a healthy lifestyle and health policy measures that makes preventive behaviours an affordable option.

Keywords:

• chronic kidney disease
• kidney cancer
• nephrolithiasis
• obesity
• prevention

Introduction

In 2014, over 600 million adults worldwide, 18 years and older, were obese. Obesity is a potent risk factor for the development of kidney disease. It increases the risk of developing major risk factors for chronic kidney disease (CKD), like diabetes and hypertension, and it has a direct impact on the development of CKD and end-stage renal disease (ESRD). In individuals affected by obesity, a (likely) compensatory mechanism of hyperfiltration occurs to meet the heightened metabolic demands of the increased bodyweight. The increase in intraglomerular pressure can damage the kidney structure and raise the risk of developing CKD in the long term.

The good news is that obesity, as well as the related CKD, is largely preventable. Education and awareness of the risks of obesity and a healthy lifestyle, including proper nutrition and exercise, can dramatically help in preventing obesity and kidney disease. This article reviews the association of obesity with kidney disease on the occasion of the 2017 World Kidney Day.

Epidemiology of obesity in adults and children

Over the last three decades, the prevalence of overweight and obese adults (BMI ≥ 25 kg/m²) worldwide has increased substantially.¹ In the United States, the age-adjusted prevalence of obesity in 2013–2014 was 35% among men and 40.4% among women.² The problem of obesity also affects children. In the United States in 2011–2014, the prevalence of obesity was 17% and extreme obesity 5.8% among youth 2–19 years of age. The rise in obesity prevalence is also a worldwide concern,^3,4 as it is projected to grow by 40% across the globe in the next decade. Low- and middle-income countries are now showing evidence of transitioning from normal weight to overweight and obesity as parts of Europe and the United States did decades ago.⁵ This increasing prevalence of obesity has implications for cardiovascular disease (CVD) and also for CKD. A high body mass index (BMI) is one of the strongest risk factors for new-onset CKD.^6,7

Definitions of obesity are most often based on BMI (i.e. weight [kilograms] divided by the square of his or her height [metres]). A BMI between 18.5 and 25 kg/m² is considered by the World Health Organization (WHO) to be normal weight, a BMI between 25 and 30 kg/m² as overweight, and a BMI of > 30 kg/m² as obese. Although BMI is easy to calculate, it is a poor estimate of fat mass distribution, as muscular individuals or those with more subcutaneous fat may have a BMI as high as individuals with larger intra-abdominal (visceral) fat. The latter type of high BMI is associated with a substantially higher risk of metabolic and cardiovascular disease. Alternative parameters to capture visceral fat more accurately include waist circumference (WC) and a waist:hip ratio (WHR) of > 102 cm and 0.9, respectively, for men and > 88 cm and > 0.8, respectively, for women. WHR has been shown to be superior to BMI for the correct classification of obesity in CKD.

Association of obesity with CKD and other renal complications

Numerous population-based studies have shown an association between measures of obesity and both the development and the progression of CKD (Table 1). Higher BMI is associated with the presence⁸ and development^9–11 of proteinuria in individuals without kidney disease. Furthermore, in numerous large population-based studies, higher BMI appears associated with the presence^8,12 and development of low estimated GFR,^9,10,13 with more rapid loss of estimated GFR over time,¹⁴ and with the incidence of ESRD.^15–18 Elevated BMI levels (class II obesity and above) have been associated with more rapid progression of CKD in patients with pre-existing CKD.¹⁹ A few studies examining the association of abdominal obesity using WHR or WC with CKD describe an association between higher girth and albuminuria,²⁰ decreased GFR⁸ or incident ESRD²¹ independent of BMI level.

Table 1: Studies examining the association of obesity with various measures of CKD

Study	Patients	Exposure	Outcomes	Results	Comments
Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study^8	7 676 Dutch individuals without diabetes	Elevated BMI (overweight and obese*), and central fat distribution (waist:hip ratio)	- Presence of urine albumin 30–300 mg/24 h - Elevated and diminished GFR	- Obese + central fat: higher risk of albuminuria - Obese +/- central fat: higher risk of elevated GFR - Central fat +/- obesity associated with diminished filtration	Cross-sectional analysis
Multinational study of hypertensive outpatients^20	20 828 patients from 26 countries	BMI and waist circumference	Prevalence of albuminuria by dipstick	Higher waist circumference associated with albuminuria independent of BMI	Cross-sectional analysis
Framingham Multi-Detector Computed Tomography (MDCT) cohort^22	3 099 individuals	Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT)	Prevalence of UACR > 25 mg/g in women and > 17 mg/g in men	VAT associated with albuminuria in men, but not in women	Cross-sectional analysis
CARDIA (Coronary Artery Risk Development in Young Adults) study^11	2 354 community-dwelling individuals with normal kidney function aged 28–40 years	Obesity (BMI > 30 kg/m^2) Diet and lifestyle-related factors	Incident microalbuminuria	Obesity (OR 1.9) and unhealthy diet (OR 2.0) associated with incident albuminuria	Low number of events
Hypertension Detection and Follow-Up Program^10	5 897 hypertensive adults	Overweight and obese BMI* vs. normal BMI	Incident CKD (1+ or greater proteinuria on urinalysis and/or an eGFR < 60 ml/min/1.73 m^2)	Both overweight (OR 1.21) and obesity (OR 1.40) associated with incident CKD	Results unchanged after excluding diabetics
Framingham Offspring Study^9	2 676 individuals free of CKD stage 3	High vs. normal BMI*	Incident CKD stage 3 Incident proteinuria	Higher BMI not associated with CKD3 after adjustments Higher BMI associated with increased odds of incident proteinuria	Predominantly white, limited geography
Physicians’ Health Study^13	11 104 initially healthy men in US	BMI quintiles Increase in BMI over time (vs. stable BMI)	Incident eGFR < 60 ml/min/1.73 m^2	Higher baseline BMI and increase in BMI over time both associated with higher risk of incident CKD	Exclusively men
Nationwide US Veterans Administration cohort^14	3 376 187 US veterans with baseline eGFR ≥60 mL/min/1.73 m^2	BMI categories from < 20 to > 50 kg/m^2	Rapid decline in kidney function (negative eGFR slope of > 5 ml/min/1.73 m^2)	BMI > 30 kg/m^2 associated with rapid loss of kidney function	Associations more accentuated in older individuals
Nationwide population-based study from Sweden^12	926 Swedes with moderate/advanced CKD compared with 998 controls	BMI ≥ 25 vs. < 25 kg/m^2	CKD vs. no CKD	Higher BMI associated with 3x higher risk of CKD	Risk strongest in diabetics, but also significantly higher in non-diabetics Cross-sectional analysis
Nationwide population-based study in Israel^17	1 194 704 adolescent males and females examined for military service	Elevated BMI (overweight and obesity) vs. normal BMI*	Incident ESRD	Overweight (HR 3.0) and obesity (HR 6.89) associated with higher risk of ESRD	Associations strongest for diabetic ESRD, but also significantly higher for non-diabetic ESRD
The Nord-Trøndelag Health Study (HUNT-1)^15	74 986 Norwegian adults	BMI categories*	Incidence of ESRD or renal death	BMI > 30 kg/m^2 associated with worse outcomes	Associations not present in individuals with BL < 120/80 mmHg
Community-based screening in Okinawa, Japan^16	100 753 individuals > 20 years old	BMI quartiles	Incidence of ESRD	Higher BMI associated with increased risk of ESRD in men, but not in women	Average BMI lower in Japan compared with Western countries
Nationwide US Veterans Administration cohort^19	453 946 US veterans with baseline eGFR< 60 ml/min per 1.73 m^2	BMI categories from < 20 to > 50 kg/m^2	- Incidence of ESRD - Doubling of serum creatinine - Slopes of eGFR	Moderate and severe obesity associated with worse renal outcomes	Associations present but weaker in patients with more advanced CKD
Kaiser Permanente Northern California^18	320 252 adults with and without baseline CKD	Overweight, class I, II and extreme obesity vs. normal BMI*	Incidence of ESRD	Linearly higher risk of ESRD with higher BMI categories	Associations remained present after adjustment for DM, hypertension and baseline CKD
REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study^21	30 239 individuals	Elevated waist circumference or BMI	Incidence of ESRD	BMI above normal not associated with ESRD after adjustment for waist circumference	Association of waist circumference with ESRD became non-significant after adjustment for comorbidities and baseline eGFR and proteinuria

Notes:

BMI = body mass index; CKD = chronic kidney disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; HR = hazard ratio; OR = odds ratio; UACR = urine albumin–creatinine ratio.

* Normal weight: BMI 18.5 to 24.9 kg/m²; overweight: BMI 25.0 to 29.9 kg/m²; class I obesity: BMI 30.0 to 34.9 kg/m²; class II obesity: BMI 35.0 to 39.9 kg/m²; class III obesity: BMI ≥ 40 kg/m².

Higher visceral adipose tissue measured by computed tomography has been associated with a higher prevalence of albuminuria in men.²² The observation of a BMI-independent association between abdominal obesity and poorer renal outcomes is also described in relationship with mortality in patients with ESRD²³ and kidney transplant,²⁴ and suggests a direct role of visceral adiposity. In general, the associations between obesity and poorer renal outcomes persist even after adjustments for possible mediators of obesity’s cardiovascular and metabolic effects, such as high blood pressure and diabetes mellitus, suggesting that obesity may affect kidney function through mechanisms in part unrelated to these complications (vide infra).

The deleterious effect of obesity on the kidneys extends to other complications such as nephrolithiasis and kidney malignancies. Higher BMI is associated with an increased prevalence²⁵ and incidence^26,27 of nephrolithiasis. Furthermore, weight gain over time and higher baseline WC were also associated with higher incidence of nephrolithiasis.²⁷ Obesity is associated with various types of malignancies, particularly cancers of the kidneys. In a population-based study of 5.24 million individuals from the UK, a 5 kg/m² higher BMI was associated with a 25% higher risk of kidney cancers, with 10% of all kidney cancers attributable to excess weight.²⁸ Another large analysis examining the global burden of obesity on malignancies estimated that 17% and 26% of all kidney cancers in men and women, respectively, were attributable to excess weight.²⁹ The association between obesity and kidney cancers was consistent in both men and women, and across populations from different parts of the world in a meta-analysis that included data from 221 studies (of which 17 examined kidney cancers).³⁰ Among the cancers examined in this meta-analysis, kidney cancers had the third highest risk associated with obesity (relative risk per 5 kg/m² higher BMI 1.24, 95% CI 1.20–1.28, p < 0.0001).³⁰

Mechanisms of action underlying the renal effects of obesity

Obesity results in complex metabolic abnormalities that have wide-ranging effects on diseases affecting the kidneys. The exact mechanisms whereby obesity may worsen or cause CKD remain unclear. The fact that most obese individuals never develop CKD, and the distinction of up to as many as 25% of obese individuals as ‘metabolically healthy’ suggests that increased weight alone is not sufficient to induce kidney damage.³¹ Some of the deleterious renal consequences of obesity may be mediated by downstream comorbid conditions such as diabetes mellitus or hypertension, but there are also effects of adiposity that could impact the kidneys directly, induced by the endocrine activity of the adipose tissue via production of (among others) adiponectin,³² leptin³³ and resistin³⁴ (Figure 1). These include the development of inflammation,³⁵ oxidative stress,³⁶ abnormal lipid metabolism,³⁷ activation of the renin–angiotensin–aldosterone system,³⁸ and increased production of insulin and insulin resistance.^39,40

Figure 1: Putative mechanisms of action whereby obesity causes chronic kidney disease.

These various effects result in specific pathologic changes in the kidneys,⁴¹ which could underlie the higher risk of CKD seen in observational studies. These include ectopic lipid accumulation⁴² and increased deposition of renal sinus fat,^43,44 the development of glomerular hypertension and increased glomerular permeability caused by hyperfiltration-related glomerular filtration barrier injury,⁴⁵ and ultimately the development of glomerulomegaly,⁴⁶ and focal or segmental glomerulosclerosis⁴¹ (Figure 2). The incidence of so-called obesity-related glomerulopathy (ORG) has increased tenfold between 1986 and 2000.⁴¹ Importantly, ORG often presents along with pathophysiologic processes related to other conditions or advanced age, conspiring to result in more accentuated kidney damage in patients with high blood pressure⁴⁷ or in the elderly.^14,39

Figure 2: Obesity-related perihilar focal segmental glomerulosclerosis on a background of glomerulomegaly. Periodic Acid-Schiff stain, original magnification 400x.

Courtesy of Dr Patrick D. Walker, MD; Arkana Laboratories, Little Rock, AR.

Obesity is associated with a number of risk factors contributing to the higher incidence and prevalence of nephrolithiasis. Higher body weight is associated with lower urine pH⁴⁸ and increased urinary oxalate,⁴⁹ uric acid, sodium and phosphate excretion.⁵⁰ Diets richer in protein and sodium may lead to a more acidic urine and decrease in urinary citrate, also contributing to kidney stone risk. The insulin resistance characteristic of obesity may also predispose to nephrolithiasis⁵¹ through its impact on tubular Na–H exchangers⁵² and ammoniagenesis,⁵³ and the promotion of an acidic milieu.⁵⁴ Complicating the picture is the fact that some weight loss therapies result in a worsening, rather than an improvement, in the risk for kidney stone formation; e.g. gastric surgery can lead to a substantial increase in enteral oxalate absorption and enhanced risk of nephrolithiasis.⁵⁵

The mechanisms behind the increased risk of kidney cancers observed in obese individuals are less well characterised. Insulin resistance, and the consequent chronic hyperinsulinemia and increased production of insulin-like growth factor 1 and numerous complex secondary humoral effects may exert stimulating effects on the growth of various types of tumour cells.⁵⁶ More recently, the endocrine functions of adipose tissue,⁵⁷ its effects on immunity,⁵⁸ and the generation of an inflammatory milieu with complex effects on cancers^59,60 have emerged as additional explanations.

Obesity in patients with advanced kidney disease: the need for a nuanced approach

Considering the foregoing evidence concerning the overwhelmingly deleterious effects of obesity on various disease processes, it is seemingly counterintuitive that obesity has been consistently associated with lower mortality rates in patients with advanced CKD^19,61 and ESRD.^62,63 Similar ‘paradoxical’ associations have also been described in other populations, such as in patients with congestive heart failure,⁶⁴ chronic obstructive pulmonary disease,⁶⁵ rheumatoid arthritis,⁶⁶ and even in old individuals.⁶⁷ It is possible that the seemingly protective effect of a high BMI is the result of the imperfection of BMI as a measure of obesity, as it does not differentiate the effects of adiposity from those of higher non-adipose tissue. Indeed, studies that separated the effects of a higher waist circumference from those of higher BMI showed a reversal of the inverse association with mortality.^23,24 Higher muscle mass has also been shown to explain at least some of the positive effects attributed to elevated BMI.^63,68 However, there is also evidence to suggest that higher adiposity, especially subcutaneous (non-visceral) fat, may also be associated with better outcomes in ESRD patients.⁶² Such benefits may indeed be present in patients who have very low short-term life expectancy, such as most ESRD patients.⁶⁹ Indeed, some studies that examined the association of BMI with time-dependent survival in ESRD have shown a marked contrast between protective short-term effects vs. deleterious longer term effects of higher BMI.⁷⁰ There are several putative short-term benefits that higher body mass could portend, especially to sicker individuals. These include a benefit from the better nutritional status typically seen in obese individuals, and which provides better protein and energy reserves in the face of acute illness, and a higher muscle mass with enhanced antioxidant capacity⁶³ and lower circulating actin and higher plasma gelsolin levels,⁷¹ which are associated with better outcomes. Other hypothetically beneficial characteristics of obesity include a more stable haemodynamic status with mitigation of stress responses and heightened sympathetic and renin–angiotensin activity;⁷² increased production of adiponectines⁷³ and soluble tumour necrosis factor alpha receptors⁷⁴ by adipose tissue neutralising the adverse effects of tumour necrosis factor alpha; enhanced binding of circulating endotoxins⁷⁵ by the characteristically higher cholesterol levels seen in obesity; and sequestration of uremic toxins by adipose tissue.⁷⁶

Potential interventions for management of obesity

Obesity engenders kidney injury via direct mechanisms through deranged synthesis of various adipose tissue cytokines with nephrotoxic potential, as well as indirectly by triggering diabetes and hypertension, i.e. two conditions that rank among the strongest risk factors for CKD. Perhaps due to the survival advantage of obesity in CKD, the prevalence of end-stage kidney disease is on the rise both in the United States⁷⁷ and in Europe.⁷⁸ Strategies for controlling the obesity-related CKD epidemic at population level and for countering the evolution of CKD towards kidney failure in obese patients represent the most tantalising task that today’s health planners, health managers and nephrologists face.

Countering CKD at population level

Calls for public health interventions in the community to prevent and treat CKD at an early stage have been made by major renal associations, including the International Society of Nephrology (ISN), International Federation of the Kidney Foundation (IFKF), the European renal association (ERA-EDTA) and various national societies. In the United States, Healthy People 2020, a programme that sets 10-year health targets for health-promotion and -prevention goals, focuses on both CKD and obesity. Surveys to detect obese patients, particularly those with a high risk of CKD (e.g. hypertensive and/or diabetic obese people) and those receiving suboptimal care, to inform these patients of the potential risk for CKD they are exposed to is the first step towards developing public health interventions. Acquiring evidence that current interventions to reduce CKD risk in the obese are efficacious and deployable is an urgent priority to set goals and means for risk modification. Appropriate documentation of existing knowledge distilling the risk and the benefits of primary and secondary prevention interventions in obese people, and new trials in this population to fill knowledge gaps (see below) are needed. Finally, surveillance programmes that monitor progress on the detection of at-risk individuals and the effectiveness of prevention programmes being deployed⁷⁹ constitute the third, fundamental element for establishing efficacious CKD prevention plans at population level.

A successful surveillance system for CKD has already been implemented in some places such as the United Kingdom (UK).⁸⁰ A campaign to disseminate and apply K-DOQI CKD guidelines in primary care within the UK National Health Service was launched. This progressively increased the adoption of K-DOQI guidelines and also, thanks to specific incentives for UK general physicians to detect CKD, led to an impressive improvement in the detection and care of CKD, i.e. better control of hypertension and increased use of angiotensin-converting enzyme and angiotensin receptor blockers.⁸⁰ This system may serve as a platform to improve the prevention of obesity-related CKD. Campaigns aiming at reducing the obesity burden are now at centre stage worldwide and are strongly recommended by the WHO, and it is expected that these campaigns will reduce the incidence of obesity-related complications, including CKD. However, obesity-related goals in obese CKD patients remain vaguely formulated, largely because of the paucity of high-level-evidence intervention studies to modify obesity in CKD patients.⁸¹

Prevention of CKD progression in obese people with CKD

Observational studies in metabolically healthy obese subjects show that the obese phenotype unassociated with metabolic abnormalities per se predicts a higher risk for incident CKD,⁸² suggesting that obesity per se may engender renal dysfunction and kidney damage even without diabetes or hypertension (vide supra). In overweight or obese diabetic patients, a lifestyle intervention including caloric restriction and increased physical activity compared with a standard follow-up based on education and support to sustain diabetes treatment reduced the risk for incident CKD by 30%, although it did not affect the incidence of cardiovascular events.⁸³ Such a protective effect was partly due to reductions in bodyweight, HbA1c, and systolic BP. No safety concerns regarding kidney-related adverse events were seen.⁸³ In a recent meta-analysis collating experimental studies in obese CKD patients, interventions aimed at reducing bodyweight showed coherent reductions in blood pressure, glomerular hyperfiltration and proteinuria.⁸¹ A thorough post hoc analysis of the REIN study showed that the nephron-protective effect of ACE inhibition in proteinuric CKD patients was maximal in obese CKD patients, but minimal in CKD patients with normal or low BMI.⁸⁴ Of note, bariatric surgical intervention has been suggested for selected CKD and ESRD patients, including dialysis patients who are waitlisted for kidney transplantation.^85–87

Globally, these experimental findings provide a proof of concept for the usefulness of weight reduction and ACE inhibition interventions in the treatment of CKD in the obese. Studies showing a survival benefit of increased BMI in CKD patients, however, remain to be explained.⁸⁸ These findings limit our ability to make strong recommendations regarding the usefulness and the safety of weight reduction among individuals with more advanced stages of CKD. Lifestyle recommendations to reduce bodyweight in obese people at risk for CKD and in those with early CKD appear justified, particularly recommendations for the control of diabetes and hypertension. As the independent effect of obesity control on the incidence and progression of CKD is difficult to disentangle from the effects of hypertension and type 2 diabetes, recommendation of weight loss in the minority of metabolically healthy, non-hypertensive obese patients remains unwarranted. These considerations suggest that a therapeutic approach to overweight and obesity in patients with advanced CKD or other significant comorbid conditions has to be pursued carefully, with proper considerations of the expected benefits and potential complications of weight loss over the life span of the individual patient.

Conclusions

The worldwide epidemic of obesity affects the Earth’s population in many ways. Diseases of the kidneys, including CKD, nephrolithiasis and kidney cancers, are among the more insidious effects of obesity, but which nonetheless have wide-ranging deleterious consequences, ultimately leading to significant excess morbidity and mortality and excess costs to individuals and the entire society. Population-wide interventions to control obesity could have beneficial effects in preventing the development, or delaying the progression, of CKD. It is incumbent upon the entire healthcare community to devise long-ranging strategies towards improving the understanding of the links between obesity and kidney diseases, and to determine optimal strategies to stem the tide. The 2017 World Kidney Day is an important opportunity to increase education and awareness to that end.